Antioxidant properties of curcumin and its impact on arteriovenous fistula maturation in end-stage kidney disease patient with diabetes mellitus type 2
Int J Res Pharm Sci.2020; 11(4): 7624-7629. DOI: https://doi.org/10.26452/ijrps.v11i4.4107
| Globally, the most common cause of the end-stage kidney disease is diabetes mellitus. Although kidney transplantation is the first-line treatment option for end-stage kidney disease, most preferred is hemodialysis due to several reasons. In diabetes mellitus, vascular flow alteration plays a major role in arteriovenous fistula (AVF) maturation failure. A phytochemical component ‘curcumin’ has proven antioxidant, antiproliferative and antitumorigenic which might prevent AVF maturation failure. |
Objective:
To assess the effect of curcumin and acetylsalicylic acid on total antioxidant capacity (TAC) in end-stage kidney disease patient with diabetes mellitus type 2 (ESRD) patients.
Methods:
This is a single-blinded, randomized controlled trial in 67 end-stage kidney disease patients with diabetes mellitus type 2 patients. The subjects were randomly assigned into curcumin group (2000 mg/day), acetylsalicylic acid group (80mg/day), and placebo, supplemented for 4 weeks. All the subjects were followed-up weekly for their drug compliance, antioxidant assessment was done in 4th and 8th week follow-up. Arteriovenous fistula was considered as mature according to the national kidney foundation kidney disease outcomes quality initiative (NKF-KDOQI) guidelines.
Results:
Conclusion
Curcumin C3 Complex® at 2000 mg/day helped in arteriovenous fistula maturation among end-stage renal disease patients with type 2 diabetes by increasing antioxidant capacity.